Transforming Chronic Kidney Disease With ProKidney's Bruce Culleton, M.D.
Streams straight from the publisher. podnod never proxies or re-hosts episode audio.
We love to hear from our listeners. Send us a message.
On this week's episode of the Business of Biotech, Bruce Culleton, M.D., CEO at ProKidney, talks about moving from academic research to industry and the role a key mentor played in his career path. Bruce discusses his experiences as a first-time CEO at ProKidney, a late-stage autologous cell therapy biotech focused on pioneering new treatments for chronic kidney disease (CKD), the benefits of FDA's Regenerative Medicine Advanced Therapy (RMAT) designation, how delaying or avoiding kidney dialysis would be a game-changer for CKD patients, and more.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
We love to hear from our listeners. Send us a message.
buzzsprout.comBusiness of Biotech
lifescienceleader.comBusiness of Biotech newsletter
www9.lifescienceleader.comhttps://www.linkedin.com/in/bencomer/
linkedin.com
- 0:00Meet Bruce Culleton And ProKidney
- 1:02Why Nephrology And The Framingham Lessons
- 4:50Leaving Academia For Industry Impact
- 9:32Building Kidney Care At CVS And Value-Based Care
- 12:40Dialysis Today And The Need For Innovation
- 15:20Joining ProKidney And Becoming CEO
- 21:25How The Therapy Is Made And Delivered
- 25:12The Biggest CKD Gap: Screening And Access
- 28:55Home Dialysis, Economics, And Patient Choice
- 31:02Why Autologous Cells For Late-Stage CKD
- 34:40Trial Strategy, RMAT, And FDA Pathway
- 38:40Timeline To Readout, BLA, And Launch Plans
- 42:05Culture, Readiness, And What’s Next
- 45:15Living Donation Risks And Rewards
- 47:58Closing And Where To Subscribe